Latest News
Egetis Therapeutics receives FDA approval for EMCITATE in MCT8 deficiency
29 September 2026 - Life science investor Flerie AB (STO:FLERIE) announced on Tuesday that its portfolio company Egetis Therapeutics AB (STO:EGTX), a Swedish pharmaceutical company, has received US Food and Drug Administration approval for EMCITATE (...
AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations
29 September 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) announced on Tuesday that it has agreed to invest USD2bn in newly issued equity in biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) t...
Lakewood-Amedex Biotherapeutics reports positive data for clinical candidate Nu-3 in diabetic foot ulcers
29 September 2026 - Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT), a clinical-stage biotechnology company focused on advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin cl...
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
29 September 2026 - BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, announced on Monday its participation in the Regulatory Perspectives on H...
Viking Therapeutics closes offerings of common stock and convertible senior notes
29 September 2026 - Clinical-stage biopharmaceutical company Viking Therapeutics Inc (Nasdaq:VKTX) announced on Monday the closing of its concurrent upsized public offerings of 9,035,714 shares of common stock, at a public offering price of USD35.00 ...